To compare stone composition and serum/urine biochemistries in stone formers with multiple sclerosis (MS) against stone formers without MS and to examine the association between mobility, methods of bladder emptying, and stone formation.
Introduction
Multiple sclerosis (MS) is a demyelinating inflammatory disease affecting the CNS. It has a tendency to be progressive and often leads to declines in mobility secondary to spinal cord involvement [1] . The progressive nature of the disease in the spinal cord often leads to neurogenic lower urinary tract dysfunction. As a result, the genitourinary manifestations of MS are common and seen in >75% of patients [2] . It is also one of the most common initial presenting complaints, seen in~12% of patients [3] . A similar pathology is seen in patients with spinal cord injury (SCI). It is known that chronic and complicated stone disease is a significant source of morbidity in patients with SCI. Within 10 years of a SCI, 7% of patients will develop a kidney stone [4] .
Unlike patients with SCI, patients with MS have ongoing disease progression, intermittent exacerbations, or both. It is known that patients with SCI have upper tract stones characterised by an increased prevalence of struvite or calcium phosphate stones thought to be driven by infected urine secondary to altered bladder emptying mechanisms, neurogenic bladder, or foreign bodies [5, 6] . To our knowledge, no investigation has been performed to date characterising stone formation in patients with MS. The objective of the present study was two-fold: (i) evaluate the stone composition as well as serum and urine biochemistries in patients with MS and (ii) to examine whether mobility and bladder management strategies are risk factors in stone formation in patients with MS.
Patients and Methods
After obtaining Institutional Review Board (IRB) approval, we conducted a retrospective case-control study of patients at a large, urban academic tertiary care centre and its satellite facilities from 2001 to 2016. The data were collected retrospectively from the electronic medical records using a combination of chart review and electronic retrieval of data.
Definition of Cases and Controls
Cases consisted of all patients with at least one recorded diagnosis of MS (International Classification of Diseases, ninth revision (ICD-9), code 340.0) among our registry of stone patients. Our stone registry is an IRB-approved database consisting of patient diagnosed with nephrolithiasis based on ICD-9 code of 592.xx and 594.xx. Eligible controls were patients that did not have any diagnosis of MS. Up to two controls were selected for each case from our registry of stone patients, matched on age, body mass index (BMI), and sex. For the second part of the study, controls were patients with at least one recorded diagnosis of MS but without any diagnosis of stone disease. We identified one control for each case, matched on age, sex, and BMI. For those individuals with a history of stone disease, age was defined as the age at the diagnosis of the stone disease. For the others, age was calculated based on the last contact date at our institution. Follow-up time was calculated from time of stone diagnosis to the time of last encounter at our institution. To identify matches, propensity score matching was performed with the MatchIt package in R statistical software using the nearest neighbour approach without replacement [7] .
Urinary Stone Panel Evaluation
To analyse patient urinary risk factors for stone disease we selected those patients in this cohort who had a complete 24-h urinary collection. When more than one 24-h urinary collection was available, the first collection was chosen for analysis. Urinary collections were examined for calcium, sodium, oxalate, citrate, uric acid, pH, volume, and creatinine. Urine samples were analysed either at our institution's laboratory or at an outside facility (Litholink Corp., Chicago, IL, USA). Normal values for stone panels were as follows and have been previously described [8] : calcium <250 mg/day for men and <200 mg/day for women, sodium <150 mmol/day, oxalate <40 mg/day, citrate >450 mg/day for men and >550 mg/day for women, uric acid <800 mg/day for men and <750 mg/day for women.
Stone Composition Evaluation
For this analysis, we included patients who had at least one stone analysis available. At our institution stone composition was analysed by Fourier transform infrared spectrometry and expressed as the percentage of each component in the stone. Stone composition group was assigned based on the predominant (≥50%) crystal identified. When a patient had multiple stone composition analyses available, the earliest available composition was used. Usage information for medications known to modify stone risk was recorded (acetazolamide [9] , topimarate [10] , potassium citrate, hydrochlorothiazide, allopurinol). Presence of a bone disorder was identified through use of ICD code: osteoporosis (ICD-9 733.0x).
Stone Burden and Location
We examined stone burden and location among patients who underwent a procedure. This information was extracted before the procedure. Stone burden, as defined as the sum of the maximum stone diameter of all stone present on the side on which the procedure was performed. When available, CT scans were reviewed in the coronal and axial planes, and the largest diameter was used. A staghorn stone was defined as a stone which had a component in the renal pelvis and branched into any of the calyces.
Laboratory and Stone Procedures
Serum sodium, potassium, calcium, and creatinine values nearest to date of the 24-h urinary collection or the stone composition analysis were also extracted from the electronic medical record. Information on surgical management of nephrolithiasis was also retrieved from the electronic medical record. Procedures were identified by the Current Procedural Terminology (CPT) code and included ureteroscopy (CPT code 52352, 52353, 52356, and 52332), percutaneous nephrolithotomy (PCNL; CPT code 50080, 50081, and 50561), extracorporeal shockwave lithotripsy (CPT code 50590), and cystolithopaxy (CPT code 52317 and 52318). Information on urine nitrate and urine leucocyte esterase on all available dipsticks performed on the patients were extracted. Leucocyte esterase values of 'small', 'moderate', and 'large' were recoded as '1+', '2+', and '3+'. A positive leucocyte esterase was defined as having either '1+', '2+', or '3+'. 
Mobility and Methods of Bladder Emptying
Charts of cases and controls were reviewed to extract information on mobility and bladder emptying techniques. Mobility was classified into independent, ambulation with assistance, wheel-chair bound, and bed-bound. Bladder emptying techniques were classified as spontaneous, intermittent straight catheterisation (ISC), or indwelling catheter (Foley or suprapubic tube). Information about mobility and bladder emptying technique at a time point closest to date of stone diagnosis AE 1 year was used. Information about prior history of bladder surgeries such as ileal conduit, bladder augmentation, or the creation of a continent cutaneous channel was also collected. Patients were excluded from this analysis if information about mobility or bladder management techniques was not documented within the 1-year time-span.
Statistical Analysis
Descriptive statistics on continuous variables are reported as medians with interquartile ranges (IQRs) and compared using the Wilcoxon rank-sum test. For categorical variables, proportions (counts) are reported and compared using the Fisher's exact test. All results were considered statistically significant at the level of P < 0.05 and all tests were twosided. We tested the association between MS and positive urine culture using a mixed effects logistic regression model. This was to account for the dependency in the data due to any single patient having multiple urine dipsticks. The presence of MS was treated as a fixed effect and the patient identification as a random effect. A multivariable analysis was performed using logistic regression to evaluate the effect of mobility and bladder management techniques on the risk of stone formation. The cases and controls used for this analysis were patients with MS with and without stones and the outcome was presence of stone disease. Variables entered into the model were age, gender, BMI, mobility, and bladder emptying technique. Results were expressed as odds ratios (ORs) with 95% CIs. Statistical analyses were performed using R v3.2.3 software (the R Foundation for Statistical Computing, Vienna, Austria) and matching procedures were performed using MatchIt package (R Foundation), version 2.4-21
Results
Based on our inclusion criteria 587 patients were identified with a diagnosis of both MS and stone disease.
24-h Urinary Stone Panel
In all, 61 patients with MS and stone disease had a complete 24-h urinary stone panel analysis available. For these patients, 120 matched controls were identified. Most patients were female (66%), with median (IQR) age of 53.2 (47.0-58.1) years when they completed the first 24-h urinary stone panel. Age, gender, and BMI were similar between the cases and controls (Table 1) . Serum laboratory measures were similar across both groups with the exception of serum sodium, which showed a clinically insignificant but statistically significant decrease in the patients with MS (139 vs 140 mmol/L, P = 0.001). Urinary pH, volume, creatinine, calcium, citrate, oxalate, sodium, and uric acid were similar between the groups and there were no significant differences in hypocitraturia, hyperoxaluria, hypercalcuria, and hyperuricosuria ( Table 1 ). The median (IQR) follow-up was 3.9 (1.5-7.7) years. Patients with MS were significantly more likely to have undergone cystolithopaxy (11% vs 0%, P = 0.05) and there was a trend toward higher use of PCNL (26% vs 11%, P = 0.06). There were no significant differences in the use of ureteroscopy (63% vs 70%, P = 0.31) and extracorporeal shockwave lithotripsy (24% vs 32%, P = 0.62). 
Stone Composition
We identified 118 patients with MS and stone diagnosis with an available stone composition analysis. Patients with MS were significantly more likely to have calcium phosphate stones (42% vs 15%, P < 0.001) and struvite stones (8% vs 3%, P = 0.03). They were less likely to have calcium oxalate monohydrate stones (39% vs. 64%, P < 0.001). There were no significant differences in presence of calcium oxalate dihydrate (6% vs 10%, P = 0.31), uric acid (3% vs 9%, P = 0.08), or cystine (1% vs 0%, P = 0.34) stones (Table 2) . Patients with MS were less likely to be on allopurinol (2% vs 10%, P = 0.004), but had similar rates in the use of other medications such as hydrochlorothiazide, potassium citrate, topiramate, and acetazolamide. Those with MS were significantly more likely to have a diagnosis of osteoporosis (25% vs 14%, P = 0.01; Table 2 ).
The median (IQR) follow-up was 4.5 (2.4-7.9) years. In this cohort of patients, those with MS were more likely to have undergone a PCNL (25% vs 12%, P = 0.001) or a cystolithopaxy (16% vs 3%, P < 0.001). Because stone size and location influence the decision on the procedure, we examined these parameters for each procedure among patients with an available stone composition. Patients with MS who underwent a procedure had significantly greater stone burden (16 vs 9 mm, P < 0.001) and were more likely to have a staghorn stone (22% vs 7%, P = 0.001; Table 3 ).
Patients with MS had a greater proportion of positive nitrate (32% vs 8%) and leucocyte esterase (74% vs 34%) on urine dipsticks and positive urine cultures (52% vs 32%) ( Table 4) . Using mixed effects modelling to account for individual patients having multiple results, a diagnosis of MS was (7) 19 (22) 0.001
Stone size and location information was extracted prior to each procedure among patients who had a stone composition available. Data is from 263 unique patients. *Stone burden as defined as sum of maximum stone diameter of all stone present on the side on which the procedure was performed. When available, CT scans were reviewed in the coronal and axial planes, and the largest diameter was used. † Stone location reported only for non-staghorn stones. ‡ A staghorn stone was defined as a stone which had a component in the renal pelvis and branched into any of the calyces. We defined a positive culture as any growth showing >100 000 colony-forming units (CFUs) of at-least one organism. We excluded any cultures where the laboratory suggested contamination (n = 411). Cultures which showed >100 000 CFUs of normal urogenital flora were considered to be negative. These data include all available urine dipsticks and cultures for each patient and so a single patient can have multiple results.
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© 2017 The Authors BJU International © 2017 BJU International associated with a positive urine nitrate (OR 8.3, 95% CI 5.0-14.0; P < 0.001), positive leucocyte esterase (OR 6.9, 95% CI 3.8-12.6; P < 0.001), and positive urine culture (OR 2.9, 95% CI 1.8-4.7; P < 0.001).
Mobility and Bladder Emptying Technique
We identified 358 patients with MS who had information about mobility and bladder emptying techniques within 1 year of their stone episode. In all, 358 matched controls with MS but no history of stone disease were identified. The matched controls were similar for age and gender, but had a slightly higher BMI (27.3 vs 26.1 kg/m 2 , P = 0.04; Table 5 ). In all, 14 patients were excluded for the identification of risk factors due to presence of ileal conduit, a cutaneous catheterisation channel, or a history of bladder augmentation. After controlling for age, gender, BMI, and mobility, compared to those who could spontaneously void, those who required ISC (OR 3.50, 95% CI 1.89-6.47; P < 0.001) or an indwelling catheter (Foley or a suprapubic tube) (OR 9.78, 95% CI 4.81-19.88; P < 0.001) had significantly higher odds of having stone disease. There were a greater proportion of wheelchair-bound and bed-ridden individuals in the stone group, and this was statistically significant on univariable analysis (P < 0.001). This effect did not persist on multivariable analysis when controlling for bladder emptying technique (P = 0.10).
Discussion
In the present case-control study on the differences in stone composition and urine biomarkers of stone formation, the population of stone formers with MS were more likely to present with calcium phosphate or struvite stones when compared with a matched cohort of stone formers without MS. There were no significant differences in stone risk factors in the 24-h urinary analysis of patients with MS. Furthermore, patients with MS were more likely to have undergone PCNL or cystolithopaxy compared to their non-MS stone-forming counterparts. The use of ISC was associated with a 3.5-times increase in the odds of having stone disease. Use of an indwelling catheter had an even greater impact, with those patients at a 9.8-times greater odds of having stone disease. After accounting for their bladder management strategy, level of mobility was not significantly associated with stone disease.
The association between MS and urinary calculi has yet to be defined. Because of the involvement of the spinal cord, patients with MS share many of the common urological manifestations seen in patients with SCI. These include immobility, urinary stasis, chronic catheterisation, and recurrent UTIs [11] . Additionally, the risk of stone disease in patients with SCI is significantly higher compared to the normal population [12] .
In our present series, the incidence of struvite stones was 8% compared to 3% in controls. The increased incidence of struvite stones and urease-producing bacteria in patients with SCI has been previously reported [6, 13] . Studies show that patients with MS have increased risk of UTI and bacteriuria [14] . This suggests a shared aetiology of increased risk of UTI and struvite stone formation in patients with SCI and patients with MS.
The patients with MS in our present series were more likely to present with calcium phosphate stones (42% in patients with MS vs 15% in controls). Previous studies in patients with SCI and neurogenic bladder secondary to myelomeningocele (MMC) have shown a high incidence of calcium phosphate stones [6] . Several aetiologies for this have been proposed. There may be a relationship between calcium phosphate stones and the resorptive bone disease seen in patients with SCI and MMC as a result of immobility [15, 16] . Second, more alkaline urine pH favours the formation of calcium phosphate stones and there is an association between UTI and alkaline pH [17, 18] . Previous studies have shown a higher incidence of bacteriuria and UTI with urease producing bacteria in patients with SCI/MMC [5] . We found that there was a significant association between the diagnosis of MS and the finding of positive nitrates and positive leucocyte esterase on urine dipstick and a positive urine culture. These findings suggest that patients with MS are more likely to be colonised, as well as have symptomatic UTIs. In general, calcium phosphate stones are typically associated with high urine pH, hypercalciuria and/or hypocitraturia. In our present patient population we did not identify statistically significant differences in any of these parameters to explain our observed risk of calcium phosphate stones. This is in contrast to previous studies in patients with SCI that have shown metabolic changes, including hypercalcemia and hypocitraturia, predisposing patients to increased stone risk [19, 20] . However, our present cohort represents a heterogeneous spectrum of MS in terms of duration and severity of disease, thus it is probably difficult to detect these differences.
The management of upper tract stones appears to be different in patients with MS. We found that patients with MS were more likely to undergo PCNL compared to matched controls (19-21% of patients with MS vs 7-8% of controls). In our present series, patients with MS were more likely to present with struvite stones and it is known that such stones are associated with the formation staghorn calculi [21] . Furthermore, among the patients with MS who underwent procedures, the stone burden and prevalence of staghorn stones were significantly higher compared to the controls. The higher rate of PCNL may be due to these findings. The atypical presentation of renal colic in patients with SCI has been shown, especially in those with lesions above T6 [22] . A similar mechanism may apply that leads to the formation of large stone burdens in patients with MS.
Several studies have investigated the impact of bladder management techniques on stone risk in the SCI population but less is known about the MS population. In this analysis, patients with MS using an indwelling catheter or ISC had significantly greater odds of stone disease (9-times and 3.5-times, respectively). This adds to the evidence previously reported in patients with SCI/MMC, which showed that those with an indwelling catheter are at the higher risk of stone formation [23] [24] [25] . It is possible that this is driven by chronic infection of the urinary tract, the presence of which has been demonstrated previously [26] .
Study Limitations
There are several limitations in the present study. First, it is retrospective and subject to the biases inherent to this particular study design. Second, as is routinely seen in the general population, only a small number of patients had a complete 24-h urine chemistry testing and stone compositions. Thus, the absence of difference seen may be the result of low statistical power, rather than a true absence of a difference. Third, because we used only data from patients with a complete 24-h urine chemistry or a stone composition there is a selection bias. For example, patients who did not bring a stone for analysis or undergo a surgical intervention where stone fragments were sent for analysis would not be included in our analysis. Another important limitation in our analysis of bladder management is that the technique of management was not randomly chosen. The choice for each patient is driven by physician judgement and convenience.
Conclusion
In the present case-control cohort of patients with kidney stones and MS, we found that patients with MS are more likely to present with calcium phosphate and struvite stones. Patients with MS were more likely to have undergone PCNL. However, no significant differences were seen in the 24-h urine chemistries. For bladder emptying, patients with MS who performed ISC or required an indwelling catheter were significantly more likely to be stone formers. Clinically, these findings suggest the importance of prompt treatment of UTIs in this population and to delay the use of an indwelling catheter whenever possible.
